Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
6(100.0%)
6Total
N/A(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06493786Not ApplicableNot Yet Recruiting

Identification of Olfactory Biomarkers of Skin Cancer From Skin Odor Samples: a Pilot Study

Role: lead

NCT05735925Not ApplicableUnknown

The Role of Host-microbiota Interplay in Hidradenitis Suppurativa Pathogenesis

Role: lead

NCT05723757Not ApplicableUnknown

Autophagy Dysfunction in Hidradenitis Suppurativa

Role: lead

NCT04680624Not ApplicableUnknown

Role of Brodalumab in the Modulation of Gut Microbiome in Psoriatic Patients

Role: lead

NCT03983460Not ApplicableUnknown

Dupilumab Impact on Skin Resident Memory T Cells

Role: lead

NCT04173039Not ApplicableCompleted

Anti-Carbamylated Protein Antibodies in Psoriatic Arthritis

Role: lead

All 6 trials loaded